M. Hogan

发表

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

James Glockner, Eric J Bergstralh, Bernard F King, 2010, Journal of the American Society of Nephrology : JASN.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

J. Glockner, M. Irazabal, V. Torres, 2011, Kidney international.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

N. LaRusso, Bohyun Kim, J. Glockner, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Blood pressure in early autosomal dominant polycystic kidney disease.

Kaleab Z. Abebe, Charity G Moore, K. Bae, 2014, The New England journal of medicine.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Marie E. Edwards, T. Kline, M. Irazabal, 2018, Clinical journal of the American Society of Nephrology : CJASN.

The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein

Vicente E. Torres, Dawn S. Milliner, Peter C. Harris, 2002, Nature Genetics.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Bradley J Erickson, Laureano J Rangel, Eric J Bergstralh, 2015, Journal of the American Society of Nephrology : JASN.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Kaleab Z. Abebe, K. Bae, C. Moore, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The HALT polycystic kidney disease trials: design and implementation.

J. Miller, K. Bae, P. Thompson, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

Marie E. Edwards, D. Nagorney, P. Kamath, 2016, Journal of the American College of Surgeons.

Genomics Integration Into Nephrology Practice

J. Lieske, P. Harris, M. Hogan, 2021, Kidney medicine.

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

F. Nevens, V. Torres, P. Ruggenenti, 2013, Gastroenterology.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

B. Rovin, B. Julian, J. Novak, 2017, Journal of the American Society of Nephrology : JASN.

Closeout of the HALT-PKD trials.

Kaleab Z. Abebe, K. Bae, C. Moore, 2015, Contemporary clinical trials.

Establishing a nephrology genetic clinic.

J. Lieske, P. Harris, M. Hogan, 2021, Kidney international.

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

M. Irazabal, V. Torres, P. Harris, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

J. Lieske, M. Kretzler, D. Gipson, 2016, Kidney international.

Renal involvement in primary Sjögren's syndrome: a clinicopathologic study.

E. Matteson, M. Hogan, J. Grande, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease

Kaleab Z. Abebe, K. Bae, C. Moore, 2018, Kidney international reports.

Risk factors for hospitalization among older, incident haemodialysis patients

M. Hogan, J. McCarthy, R. Albright, 2013, Nephrology.

Evaluation and management of pain in autosomal dominant polycystic kidney disease.

M. Hogan, S. Norby, 2010, Advances in chronic kidney disease.

Analysis of the polycystin complex (PCC) in human urinary exosome–like vesicles (ELVs)

C. Ward, M. Hogan, W. Lea, 2020, Scientific Reports.

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Marie E. Edwards, Lisa E. Vaughan, W. Kremers, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Polycystic Liver Disease: The Benefits of Targeting cAMP.

N. LaRusso, T. Masyuk, M. Hogan, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

W. Kremers, N. LaRusso, J. Glockner, 2015, Mayo Clinic proceedings.

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases

N. LaRusso, V. Torres, T. Masyuk, 2013, Hepatology.

Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease

Marie E. Edwards, W. Kremers, N. Takahashi, 2019, Pancreas.

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative

W. Kremers, M. Hogan, S. Taler, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome

M. Hogan, S. Nasr, L. Cornell, 2016, Kidney international reports.

APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis

J. Lieske, J. Hodgin, M. Kretzler, 2021, Pediatric Nephrology.

Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease

M. Irazabal, P. Harris, M. Hogan, 2022, American Journal of Nephrology.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Kaleab Z. Abebe, K. Bae, A. Chapman, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Kaleab Z. Abebe, K. Bae, C. Moore, 2017, Kidney international.

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease

Marie E. Edwards, Lisa E. Vaughan, W. Kremers, 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

B. Rovin, L. Juncos, J. Lieske, 2015, Nephron.

Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection.

M. Hogan, M. El Ters, S. Erickson, 2021, Mayo Clinic proceedings.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

F. Cosio, M. Irazabal, M. Hogan, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity

J. Lieske, J. Troost, M. Hogan, 2020, Kidney international reports.

Mitochondriopathy Manifesting as Inherited Tubulointerstitial Nephropathy Without Symptomatic Other Organ Involvement

K. Hodaňová, M. Hogan, S. Nasr, 2021, Kidney international reports.

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

M. Hogan, U. Specks, F. Fervenza, 2001, Arthritis and rheumatism.

Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report

J. Craig, M. Howell, N. Evangelidis, 2021, Clinical kidney journal.

Complete Remission in the Nephrotic Syndrome Study Network.

J. Lieske, S. Hewitt, J. Hodgin, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection.

M. Hogan, D. Milliner, F. Cockerill, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Association between prior peripherally inserted central catheters and lack of functioning arteriovenous fistulas: a case-control study in hemodialysis patients.

A. Rule, S. Nyberg, M. Hogan, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire.

S. Turner, M. Hogan, V. Garovic, 2008, American journal of obstetrics and gynecology.

Incorporation of Genetic Studies in the Kidney Transplant Evaluation Clinic: The Value of a Multidisciplinary Approach

F. Cosio, M. Hogan, M. El Ters, 2022, Transplantation.

Labile hypertension, increased metanephrines and imaging misadventures.

M. Hogan, V. Garovic, C. Grant, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Teaching Point ( Section Editor : K . Kühn ) Supported by an educational grant from Labile hypertension , increased metanephrines and imaging misadventures

M. Hogan, V. Garovic, C. Grant, 2004 .

Cystic diseases of the kidneys

M. Irazabal, V. Torres, M. Hogan, 2019, Nephrology Secrets.

Germline PKHD1 mutations are protective against colorectal cancer

S. Thibodeau, G. Petersen, L. Boardman, 2011, Human Genetics.

A primary culture of mouse proximal tubular cells , established on collagen-coated membranes

Yanhong Wu, V. Torres, C. Ward, 2007 .

A novel mutation of LAMB2 in a multigenerational mennonite family reveals a new phenotypic variant of Pierson syndrome.

V. Pankratz, E. Puffenberger, K. Strauss, 2011, Ophthalmology.

Purification of exosome-like vesicles from urine.

C. Ward, M. Hogan, Christopher Y. Chen, 2013, Methods in enzymology.

Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin.

J. V. van Deursen, Yanhong Wu, V. Torres, 2011, Journal of the American Society of Nephrology : JASN.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach

Chrysta Lienczewski, Matthias Kretzler, Susan Hogan, 2012, Kidney international.

Multidimensional Data Integration Identifies Tumor Necrosis Factor Activation in Nephrotic Syndrome: A Model for Precision Nephrology

D. Adu, J. Lieske, W. Ju, 2021, medRxiv.

Characterization of PKD protein-positive exosome-like vesicles.

N. LaRusso, A. Leontovich, V. Torres, 2009, Journal of the American Society of Nephrology : JASN.

PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression.

V. Torres, P. Harris, C. Ward, 2003, Human molecular genetics.

Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult

Augustine S. Lee, M. Hogan, S. Thomé, 2002, American journal of hematology.

Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.

Robert D. Brown, M. Irazabal, V. Torres, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies

A. Behfar, M. Irazabal, V. Torres, 2017, Kidney international reports.

Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

Adriana V Gregory, Adriana V. Gregory, T. Kline, 2021, American journal of human genetics.

Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county

Adriana V Gregory, Adriana V. Gregory, J. Killian, 2020, JHEP reports : innovation in hepatology.

Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

Marie E. Edwards, V. Tasic, A. Chapman, 2016, American journal of human genetics.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Kaleab Z. Abebe, K. Bae, A. Chapman, 2017, Journal of the American Society of Nephrology : JASN.

DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis

J. Lieske, M. Hogan, J. Grande, 2017, Kidney international reports.

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)

M. Ramirez-Alvarado, C. Ward, M. Hogan, 2012, PloS one.

Detection of High Molecular Weight Light Chain Oligomers in Urinary Exosomes of Patients with AL Amyloidosis.

A. Dispenzieri, M. Ramirez-Alvarado, C. Ward, 2009 .

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.

Yves Sznajer, Ana Rita, V. Tasic, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Strategy and rationale for urine collection protocols employed in the NEPTUNE study

J. Lieske, W. Ju, M. Bitzer, 2015, BMC Nephrology.

Subfractionation, characterization and in-depth proteomic analysis of glomerular membrane vesicles in human urine

Doug W. Mahoney, Roman M. Ženka, H. R. Bergen, 2013, Kidney international.

S. Chari, E. Yi, M. Hogan, 2012, Human pathology.

Crystalglobulin-Induced Nephropathy and Keratopathy

M. Hogan, J. Grande, S. Nasr, 2019, Kidney medicine.

56-Year-old man with rash, abdominal pain, and arthralgias.

M. Hogan, Alfred G. Valles, B. Knoll, 2007, Mayo Clinic proceedings.

COVID-19 Vaccination and Glomerulonephritis

M. Hogan, S. Nasr, Ziad M. Zoghby, 2021, Kidney International Reports.

Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review

J. Craig, A. Tong, R. Gansevoort, 2021, PloS one.

Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County.

Marie E. Edwards, J. Killian, A. Chamberlain, 2019, Clinical journal of the American Society of Nephrology : CJASN.

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

R. Gansevoort, J. Drenth, M. Hogan, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease

I. Wilkinson, R. Sandford, M. Hogan, 2021, Clinical kidney journal.

A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease.

F. Jouret, M. Hogan, F. Chebib, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Kaleab Z. Abebe, K. Bae, C. Moore, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.

M. Hogan, U. Specks, F. Fervenza, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease.

M. Hogan, S. Erickson, F. Fervenza, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Epstein–Barr virus-associated nephrotic syndrome

M. Hogan, S. Khanna, S. Sethi, 2012, Clinical kidney journal.

Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease

M. Hogan, F. Chebib, 2018 .

Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials

M. Hogan, Y. Ubara, R. Rodríguez‐Gutiérrez, 2021, PloS one.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Kaleab Z. Abebe, C. Moore, A. Chapman, 2014, The New England journal of medicine.

The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression

J. Sloan, P. Erwin, M. Murad, 2017, BMC Nephrology.

Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

Marie E. Edwards, J. Sloan, D. Nagorney, 2020, Surgery.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Diego R. Martín, Kaleab Z. Abebe, J. Miller, 2012, Kidney international.

A case report of sevelamer-associated recto-sigmoid ulcers

K. Papadakis, L. W. K. Song, M. Hogan, 2016, BMC Gastroenterology.

Expanding the clinical application of the polycystic liver disease questionnaire: determination of a clinical threshold to select patients for therapy.

M. Hogan, T. Gevers, J. Drenth, 2023, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Evaluating health‐related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume

F. Nevens, M. Hogan, V. Torres, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease

A. Chapman, V. Torres, J. Bost, 2011, Blood pressure monitoring.

Development and Validation of a Disease‐Specific Questionnaire to Assess Patient‐Reported Symptoms in Polycystic Liver Disease

Marie E. Edwards, J. Sloan, P. Kamath, 2016, Hepatology.

Surface Glycosylation Profiles of Urine Extracellular Vesicles

C. Ward, M. Hogan, M. Griffin, 2013, PloS one.

Characteristics of Patients with End-Stage Kidney Disease in ADPKD

Marie E. Edwards, Lisa E. Vaughan, T. Kline, 2020, Kidney international reports.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Roman M. Ženka, J. Lieske, M. Irazabal, 2015, Journal of the American Society of Nephrology : JASN.

Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels

Kirk D. Wyatt, M. Hogan, V. Rodriguez, 2017, Journal of pediatric hematology/oncology.

All‐trans‐retinoic acid‐induced myositis: A description of two patients

M. Hogan, R. Pruthi, H. van der Vliet, 2000, American journal of hematology.

Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis

F. Nevens, M. Hogan, V. Torres, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Robert D. Brown, M. Irazabal, V. Torres, 2019, Clinical journal of the American Society of Nephrology : CJASN.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Kaleab Z. Abebe, K. Bae, C. Moore, 2018, Current hypertension reviews.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Diego R. Martín, Kaleab Z. Abebe, J. Miller, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Clinical Implementation of an Artificial Intelligence Algorithm for Magnetic Resonance-Derived Measurement of Total Kidney Volume.

Marie E. Edwards, Adriana V. Gregory, D. Blezek, 2023, Mayo Clinic proceedings.

Somatostatin analogues improve health‐related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo‐controlled trials

F. Nevens, V. Torres, J. Drenth, 2015, Alimentary pharmacology & therapeutics.

The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network

N. Carlozzi, J. Lieske, M. Kretzler, 2019, Clinical kidney journal.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Kaleab Z. Abebe, K. Bae, C. Moore, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Underestimation of liver-related mortality in the United States.

Terry M. Therneau, T. Therneau, B. Yawn, 2013, Gastroenterology.

Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)

Tammy M. McAllister, V. Ramanan, L. Roberts, 2023, Journal of Translational Medicine.

Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

Marie E. Edwards, V. Tasic, A. Chapman, 2016, American journal of human genetics.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

B. Erickson, K. Bae, A. Chapman, 2015, Journal of the American Society of Nephrology : JASN.

Underestimation of liver-related mortality in the United States.

T. Therneau, B. Yawn, W. Kim, 2013, Gastroenterology.

The HALT polycystic kidney disease trials: design and implementation.

J. Miller, M. Hogan, R. Perrone, 2010, Clinical journal of the American Society of Nephrology : CJASN.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Kaleab Z. Abebe, K. Bae, A. Chapman, 2017, Kidney international.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

N. LaRusso, Bohyun Kim, J. Glockner, 2010, Journal of the American Society of Nephrology : JASN.

Cystic diseases of the kidneys

M. Hogan, Vicente E. Torres, 2012 .

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

R. Gansevoort, J. Drenth, M. Hogan, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Examining the safety and effectiveness of a 4-week supervised exercise intervention in the treatment of frailty in patients with chronic kidney disease

C. Kennedy, M. Hogan, L. Hickson, 2023, Clinical kidney journal.